Blurbs

Analysts Offer Insights on Healthcare Companies: Steris (STE) and Enanta Pharmaceuticals (ENTA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Steris (STEResearch Report) and Enanta Pharmaceuticals (ENTAResearch Report) with bullish sentiments.

Steris (STE)

In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Steris, with a price target of $250.00. The company’s shares closed last Tuesday at $230.69.

According to TipRanks.com, Turkaly is a 3-star analyst with an average return of 4.4% and a 43.8% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, OrthoPediatrics, and Globus Medical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Steris with a $252.00 average price target.

See today’s best-performing stocks on TipRanks >>

Enanta Pharmaceuticals (ENTA)

In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals, with a price target of $116.00. The company’s shares closed last Tuesday at $61.18.

According to TipRanks.com, Buchanan has 0 stars on 0-5 stars ranking scale with an average return of -15.9% and a 32.0% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma, Hookipa Pharma, and PolyPid.

Enanta Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $83.14.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on STE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos